Use of magnetic resonance imaging in low-dose-rate and high-dose-rate prostate brachytherapy from diagnosis to treatment assessment: Defining the knowledge gaps, technical challenges, and barriers to implementation

被引:11
作者
Frank, S. J. [1 ]
Mourtada, F. [2 ]
Crook, J. [3 ]
Menard, C. [4 ,5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 1212,1400 Pressler St, Houston, TX 77030 USA
[2] Helen F Graham Canc Ctr, Dept Radiat Oncol, Newark, DE USA
[3] British Columbia Canc Agcy, Dept Surg, Ctr Southern Interior, Kelowna, BC, Canada
[4] Univ Montreal Hosp Res Ctr CRCHUM, Montreal, PQ, Canada
[5] Univ Toronto, Techna Inst, Toronto, ON, Canada
基金
美国国家卫生研究院;
关键词
Prostate cancer; Magnetic resonance imaging; Prostate brachytherapy; LDR; HDR; MRI-assisted radiosurgery; MRI physics; Pulse sequences; QUALITY-OF-LIFE; CANCER;
D O I
10.1016/j.brachy.2017.01.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MRI is rapidly evolving as an imaging tool in both low-dose-rate and high-dose-rate brachytherapy for prostate cancer. The ability of MRI to identify intraprostatic tumors and reduce uncertainties in the workflow process should enable a more accurate and precise radiation delivery approach while simultaneously improving the quality assurance process. The ability to identify functional anatomic structures adjacent to the prostate cancer could reduce or eliminate some of the more common side effects of the treatment. However, MRI is complex, and collaborative efforts and future research are required to address the current knowledge gaps, technical challenges, and barriers to widespread the implementation of MRI-assisted and MRI-guided prostate brachytherapy. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:672 / 678
页数:7
相关论文
共 29 条
[11]   Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group [J].
Grimm, Peter ;
Billiet, Ignace ;
Bostwick, David ;
Dicker, Adam P. ;
Frank, Steven ;
Immerzeel, Jos ;
Keyes, Mira ;
Kupelian, Patrick ;
Lee, W. Robert ;
Machtens, Stefan ;
Mayadev, Jyoti ;
Moran, Brian J. ;
Merrick, Gregory ;
Millar, Jeremy ;
Roach, Mack ;
Stock, Richard ;
Shinohara, Katsuto ;
Scholz, Mark ;
Weber, Ed ;
Zietman, Anthony ;
Zelefsky, Michael ;
Wong, Jason ;
Wentworth, Stacy ;
Vera, Robyn ;
Langley, Stephen .
BJU INTERNATIONAL, 2012, 109 :22-29
[12]  
Kollmeier MA, 2017, BRACHYTHERAPY
[13]   Development of a magnetic resonance imaging protocol to visualize encapsulated contrast agent markers in prostate brachytherapy recipients: initial patient experience [J].
Lim, Tze Yee ;
Kudchadker, Rajat J. ;
Wang, Jihong ;
Bathala, Tharakeswara ;
Szklaruk, Janio ;
Pugh, Thomas J. ;
Mahmood, Usama ;
Ibbott, Geoffrey S. ;
Frank, Steven J. .
JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (03) :235-242
[14]   Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI markers for MRI-based prostate postimplant assessment [J].
Lim, Tze Yee ;
Kudchadker, Rajat J. ;
Wang, Jihong ;
Stafford, R. Jason ;
MacLellan, Christopher ;
Rao, Arvind ;
Ibbott, Geoffrey S. ;
Frank, Steven J. .
MEDICAL PHYSICS, 2016, 43 (07) :4312-4322
[15]  
Ma J, 2017, BRACHYTHERAPY
[16]  
Mahmood, 2017, BRACHYTHERAPY
[17]   MRI-guided HDR prostate brachytherapy in standard 1.5T scanner [J].
Ménard, C ;
Susil, RC ;
Choyke, P ;
Gustafson, GS ;
Kammerer, W ;
Ning, H ;
Miller, RW ;
Ullman, KL ;
Crouse, NS ;
Smith, S ;
Lessard, E ;
Pouliot, J ;
Wright, V ;
McVeigh, E ;
Coleman, CN ;
Camphausen, K .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05) :1414-1423
[18]  
Menard C, 2017, BRACHYTHERAPY
[19]  
*NCCN, CLIN PRACT GUID ONC
[20]   Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil [J].
Pugh, Thomas J. ;
Mahmood, Usama ;
Swanson, David A. ;
Munsell, Mark F. ;
Wang, Run ;
Kudchadker, Rajat J. ;
Bruno, Teresa L. ;
Frank, Steven J. .
BRACHYTHERAPY, 2015, 14 (02) :160-165